Ligand id: 6890

Name: omalizumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: omalizumab

1. Arm JP, Bottoli I, Skerjanec A, Floch D, Groenewegen A, Maahs S, Owen CE, Jones I, Lowe PJ. (2014)
Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.
Clin. Exp. Allergy, 44 (11): 1371-85. [PMID:25200415]
2. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. (2001)
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
J. Allergy Clin. Immunol., 108 (2): 184-90. [PMID:11496232]
3. Lowman HB, Presta LG, Jardieu PM, Lowe J. (1999)
Anti-IgE antibodies and methods of improving polypeptides.
Patent number: US5994511. Assignee: Genentech, Inc.. Priority date: 02/07/1997. Publication date: 30/11/1999.